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ABSTRACT
Endothelial glycocalyx layer (EGL) coating the luminal surface of vascular endothelium plays an
essential role in maintaining the normal fluid homeostasis of the body. This highly fragile layer
can be damaged by a number of pathophysiological conditions and interventions. Disease state
management should be directed to maintain EGL integrity to improve patient’s outcome. When
intravenous (IV) fluids are used, appropriate type, rate and amount of fluid should be determined
by the pathophysiology of the condition and measures to maintain the integrity of the EGL. This
review depicts the structure and function of the EGL, its alteration in common pathological states
and the rationale of IV fluid management to preserve EGL in such conditions.
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INTRODUCTION
Glycocalyx, the sugar protein coating of the vascular
endothelium, forms an integral part of the vascular
barrier and contributes to 2% of the plasma volume
[Figure 1a]. The endothelial glycocalyx layer (EGL)
plays a pivotal role in body fluid homeostasis,
modulation of inflammatory reactions, adhesion of
platelets and leukocytes and is breached in conditions
such as trauma, sepsis, diabetes, electrolyte imbalance,
surgery and overzealous fluid management.[1,2]
Intravenous (IV) fluid administration plays an integral
part in the management of a patient. As described
by Malbrain et al.,[3] there are four major indications
for IV fluid administration, namely, resuscitation,
maintenance and supplementation of fluid and
electrolytes, as a carrier for IV drugs and for parenteral
nutrition. Improper administration of IV fluid
can cause serious alteration of normal physiology
including damage of the vital EGL layer.
This review was undertaken to describe the structure,
physiology and functional basis of the EGL, its relevance
in body fluid homeostasis and IV fluid management in
various clinical and pathological conditions.
6

A thorough literature search was done from
inception to September 2018 using databases/search
engines (Medline, Embase, Scopus, PubMed, Google
Scholar and websites of National Societies for IV
fluid management). The articles were manually
searched by the authors for cross‑referencing. All
the articles published in English were searched.
We used the following keywords “endothelial
glycocalyx,” “intravenous fluid therapy,” “fluid
homeostasis,” “Starling equation,” “Revised
Starling equation,” “Liver failure,” “Nephrotic
syndrome,” “Heart failure,” “Oedema,” “Albumin,”
“Sepsis” and “ARDS.” The relevant information
pertinent to the role of EGL in various conditions
were included.
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STRUCTURE OF EGL
The composition of the EGL varies according to the
microenvironment. The most prominent constituents
of EGL are proteoglycan, glycoproteins and
glycosaminoglycans (GAGs) along with other soluble
components such as proteins [primarily albumin
along with antithrombin‑III (ATIII), apolipoproteins],
hormones, enzymes such as extracellular superoxide
dismutase‑3 (SOD3), angiotensin‑converting enzyme,
growth factors, chemokines and adhesion molecules
(selectins and integrins)[1] [Figure 1b].
The central protein core is made up of proteoglycans
to which the negatively charged highly sulphated
GAGs remain attached. Syndecan and glypicans are
the major proteoglycans having a firm connection to
the cell membrane forming the backbone of the EGL.
The other proteoglycans such as mimecan, perlecan
and biglycan are secreted later and contribute to the
soluble portion of the glycocalyx.[1]
There are five types of GAG chains, namely, heparan
sulphate, chondroitin sulphate, dermatan sulphate,
keratan sulphate and hyaluronan (or hyaluronic acid).
Hyaluronic acid is the only nonsulphated, uncharged
GAG not usually attached to any core protein. It is
usually attached to cell surface proteins (CD44)[4] and
forms a viscous solution by exhibiting water‑retaining
characteristics. Glycocalyx forms a meshwork in
which proteins and soluble GAGs get attached. It has
a fixed part which remains attached to the endothelial
layer and a dynamic part, which is in equilibrium
with circulating blood volume. Proteins <70 kDa such
as extracellular SOD, ATIII and albumin are present
in the dynamic part of the EGL layer which have
variable structure and composition [Figure 1b]. The
adhesion molecules such as platelet endothelial cell
adhesion molecule (PECAM), vascular cell adhesion

a

molecule (VCAM) and intercellular adhesion
molecule (ICAM) are also embedded within the
structures.
The presence of sulphated GAGs renders a negative
charge to the glycocalyx. Hence, its interaction varies
with varying charge of molecules and also acts as a
barrier repelling the negatively charged molecules
like red blood cell (RBC), white blood cell (WBC)
and platelets, forming a “cell exclusion zone.”
The layer also acts as a sieve, restricting passage
of molecules >70 kDa. However, the amphoteric
nature of albumin and size of 67kDa helps it to bind
tightly to the glycocalyx. Some albumin even leaks
through the glycoprotein layers. This attachment of
albumin reduces the hydraulic conductivity across
vasculature.[1]
There are several techniques to visualise the vital EGL
layer both in vivo and in vitro. In vitro visualisation
started with transmission electron microscopy which
gained accuracy over decades by development of
glycocalyx‑sparing fixation techniques. In vivo
techniques comprise confocal laser scanning
microscopy which allows 3D reconstruction of the
EGL. However, its less penetration makes it less useful
in visualising EGL of large vessels. Two‑photon laser
scanning microscopy is one of the most promising
technique allowing fairly accurate EGL visualisation
both in vivo and in vitro.[5] Real‑time visualisation by
handheld videomicroscopy is the latest trend. Based
on the mean distance between RBC and vessel wall, an
assessment of EGL thickness is calculated by post hoc
software analysis.[6]

FUNCTIONAL IMPORTANCE OF GLYCOCALYX
The negatively charged GAGs are arranged like branches
covering the glycoprotein receptors[1,7] [Figure 2]. The

b

Figure 1: Structure of endothelial glycocalyx (EGL). (a) 2% of the non‑circulating portion of the intravascular volume formed by EGL. RBC, WBC
and platelets are excluded from the non‑circulating EGL, which is in dynamic equilibrium with plasma. (b) Structure and various constituents of
EGL layer. RBC – Red Blood Cell, WBC – White Blood Cell, Alb – Albumin, SOD – Superoxide dismutase, ATIII – Antithrombin III
7
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adhesion receptors are therefore protected by the
GAG branches. These receptors are mostly of two
types: selectins and immunoglobulins. Histamine,
thrombin, interleukins and tumor necrosis factor bind
to the selectin while immunoglobulins have adhesive
molecules for ICAM, VCAM and PECAM.
External or internal insults like loss of flow
(thrombosis, arteriosclerosis), inflammation (systemic
inflammatory response, diabetes, trauma, sepsis)
and rapid administration of fluid can damage the
glycocalyx. This results in exposure of the receptors
of the glycocalyx to combine with the noxious ligands
that result in signal transduction. Hence, damage to
glycocalyx significantly affects the microcirculation.[8]

REVISED STARLING PRINCIPLE
As per Starling’s model,[9] the net force at the
arteriolar end of the capillaries pushes fluid out
as a result of high hydrostatic pressure and at the
venous end fluid re‑enters the vessels because of
osmotic attraction. The Starling equation reads as
follows: Jv = Kf ([Pc − Pi] – σ [πc − πi]), where Jv is

Figure 2: Protective mechanism of EGL. Adhesion molecules remain
embedded in EGL layer refraining adhesion of endothelial cells and
inflammatory mediators. Gp – Glycoprotein, Pg – Proteoglycan,
ICAM – Intercellular Adhesion Molecule, VCAM – Vascular Cell
Adhesion Molecule, PECAM – Platelet Endothelial Cell Adhesion
Molecule

the net fluid movement between compartments and
[Pc − Pi] − σ [πc − πi] is the net driving force, Pc is
the capillary hydrostatic pressure, Pi is the interstitial
hydrostatic pressure, πc is the capillary oncotic
pressure, πi is the interstitial oncotic pressure, Kf is
the filtration coefficient – a proportionality constant,
and σ is the reflection coefficient). Starling stated that
these forces are balanced [Figure 3a].
However, it was later demonstrated that the effect of
πi on transvascular fluid exchange is significantly less
than predicted by the standard Starling’s equation
due to the presence of EGL.[10] Hence, the revised
Starling’s principle considers the presence of EGL
which comprises adsorbed albumin molecules and
exerts a significant osmotic pressure than interstitium
as was thought earlier. Just below the EGL, there is an
empty subglycoclyx space[11] [Figure 4]. Albumin is
transported across the cell membrane by the process
of endocytosis, whereas the circulating albumin in
the blood is adsorbed over the GAG side chains and
contributes to the soluble layer of the EGL. The zone
below the soluble portion of EGL is an acellular zone
also known as the red cell exclusion zone. The adsorbed
albumin in the soluble portion of EGL contributes to
60% of colloid osmotic pressure (COP) of the total
intravascular COP that is higher than the circulating
plasma. Hence, an osmotic gradient is created
between the EGL and subglycocalyx zone (protein‑free
zone in the intercellular cleft between cells below
the glycocalyx). The revised Starling’s equation
incorporates πg (glycocalyx oncotic pressure) instead
of πi, and is stated as Jv = Kf ([Pc − Pi] − σ [πc − πg])
[Figure 3b].
Hence, the oncotic pressure difference is not built up
between the intravascular and the interstitial tissue
spaces, but within a small protein‑free zone beneath
the glycocalyx surface layer (subglycocalyx space).
The capillary hydrostatic pressure and subglycocalyx

a

b

Figure 3: (a) Original Starling’s equation Jv – Kf ([Pc – Pi] – σ [πc – πi]. Fluid pushed out at the arteriolar end equals fluid reabsorbed at the
venular end. (b) Modified Starling’s equation taking EGL layer into consideration Jv – Kf ([Pc – Pi] – σ [πc – πg]). Lymph plays a major role in
returning fluid back into the circulation
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EGL AND FLUID THERAPY

pressure help draw the fluid in the interstitial space.
This fluid that filters out forms the “ultrafiltrate.” In the
interstitium, the hydrostatic and the osmotic pressure
are much low, hence negligible fluid goes back to the
capillaries at the venous end to cause any venous
reabsorption. The lymphatics play all important role to
remove the excess fluid which comes to the interstitial
space and is put back into circulation [Figure 4]. The
revised Starling’s equation states that (a) intravascular
volume comprises circulating RBC volume, plasma
volume and glycocalyx volume instead of only plasma
and cellular elements, (b) ultrafiltrate is produced
due to filtration across glycocalyx and no venous
reabsorption occurs at the venous end and (c) lymph
forms the major route for return of fluid into circulation
as it removes the fluid from the interstitial space.

IV fluid should be administered when the fluid or
electrolyte needs cannot be met orally or enterally or
IV fluid has to be given as a medium for giving drugs.
As per the National Institute of Health and Care
Excellence (NICE) guidelines,[12] 5 Rs (Resuscitation,
Routine maintenance, Replacement, Redistribution and
Reassessment) should be kept in mind while prescribing
IV fluids and early de‑escalation is warranted.
Crystalloids are solution of inorganic ions
and small organic molecules in water and are
divided according to tonicity in to iso, hypo or
hypertonic solutions. Overadministration of acidic
crystalloids with strong ion difference like normal
saline (NS) with chloride of 153 mmol/L can lead
to hyperchloremic metabolic acidosis and damage
the EGL and result in acute kidney injury (AKI) and
impaired clotting functions[13] [Figure 5a]. Rapid NS
administration can initiate excess plasmin activity
and auto‑heparinisation from EGL shedding resulting
in diffuse coagulopathy specially in a background
of trauma or sepsis.[14,15] Balanced crystalloids like
lactated Ringer (Cl 109 mmol/L) and plasmalyte
A (Cl 98 mmol/L) are more physiological and are similar
in composition to human plasma [Figure 5b]. They are
more compatible with EGL. Large randomised clinical
trials like SMART[16] and SALTED[17] in both critically
ill and noncritically ill patients have shown that major
adverse renal events (AKI and requirement of renal

Figure 4: The oncotic pressure difference is build up between the
adsorbed albumin in the soluble EGL layer a small protein free
zone (subglycocalyx space) leading to the revised Starling’s equation

a

b

c
Figure 5: (a) Distribution and excretion of normal saline (0.9% NS) after intravenous administration. The high chloride load is above physiological
limit and can contribute to hyperchloremic metabolic acidosis. (b) Distribution, metabolism and excretion of balanced salt solution (Ringers lactate
and Plasmalyte A) with intact EGL layer. (c) Distribution and excretion of balanced salt solution (Ringers lactate and Plasmalyte A) with damaged
EGL layer leading to edema formation. ECF – Extracellular fluid, RL – Ringer’s Lactate, PL – Plasmalyte A, Cl‑ – Chloride, HCO3— – Bicarbonate
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replacement therapy) are less with administration of
balanced salt solution having low chloride content
(<110 mmol/L) compared with NS. However, balanced
crystalloids are hypotonic compared with extracellular
fluid and are associated with metabolic alkalosis, hence
they are not completely harmless. With damaged EGL,
the distribution of the balanced salt solution changes
contributing to interstitial oedema [Figure 5c].
Colloids due to their large molecular size are expected to
stay in the intravascular space for a longer time thereby
creating an increase in oncotic pressure. Colloids
commonly used are natural (albumin) or artificial
(gelatin, dextran and hydroxy ethyl starch). Albumin
has lower molecular size (67 kDa) and is part of soluble
part of EGL.[18] Presence of hypoalbuminaemia has
shown to contribute to increased EGL damage in trauma
and sepsis along with increased leakage of albumin into
the interstitial space when compared with patients with
normal albumin levels. Albumin (5%) helps maintain
the integrity of the EGL and is advised as an early
modality of treatment in trauma with the exception
of traumatic brain injury.[19] Artificial/semisynthetic
colloid administration is associated with increased
incidence of anaphylactoid reactions, coagulopathy
and AKI. Newer generation 6% hydroxy ethyl
starch (HES) (130/0.42) was presumed to offer a wider
safety and efficacy range. However, Scandinavian[20]
and CHEST[21] trials have demonstrated increased
long‑term mortality and AKI.
Revised Starling equation’s implication
At subnormal capillary pressure, infusion of colloid
solution preserves plasma COP, raises capillary
pressure and increases Jv. While infusion of crystalloids
also raises capillary pressure, it lowers COP and thus
increases Jv more than the same colloid solution
volume. At subnormal capillary pressure, infusion of
crystalloid is therefore a better choice as first line of
fluid management [Figure 6a].
Inflammation,
trauma,
shock
(hypovolemic,
septic), hyperglycemia, ischaemia and reperfusion,
electrolyte imbalance and iatrogenic causes like rapid
administration of fluids and surgery cause damage to
the EGL. Ageing, lack of moderate exercise, high‑sugar
diet and smoking are also important predisposing
factors that contribute to EGL damage.
EGL takes 6–8 h to regenerate under normal
physiological conditions. In pathological conditions,
the regeneration time varies from hours to days

a

b

Figure 6: (a) Distribution of various commonly used fluids (crystalloids
and colloids) in different body compartments. (b) Composition of
various transcellular fluids in human body and the type of replacement
fluids to be used depending on the type of fluid loss. RL – Ringer’s
Lactate, PL – Plasmalyte A, NS – Normal Saline, D5W – 5% Dextrose,
Na+ – Sodium, K+ – Potassium, Cl‑ – Chloride, HCO3‑ – Bicarbonate

depending on the extent of the ongoing insult and the
volume of glycocalyx damaged. In experimental model
of enzymatic degradation, EGL takes 5–7 days or more
to attain the previous thickness.[22]
Rapid administration of IV fluid can cause damage
to the EGL in healthy volunteers.[23] However, in
hypovolemic or septic shock, IV fluids should be
administered through large veins via large bore cannula
to avoid fluid jet to prevent damage to the delicate EGL
grid. Current evidence suggests that blood products
and IV fluids more than 500 mL should be warmed
to 37°C which helps in maintaining the core body
temperature and protects the EGL.[24]
EGL is destroyed by large volume of fluids or
hypervolemia. Atrial natriuretic peptide released
from the stretching of atria is considered to be one of
the triggers for EGL destruction. NICE guidelines[12]
recommend routine maintenance of 25–30 mL/kg/day
of water, 1 mmol/kg/day of potassium, sodium and
chloride and 50–100 g/day of glucose in patients
requiring IV fluids. Addition of glucose is to limit
starvation ketoacidosis. However, in old and frail
patients with renal impairment and cardiac failure, the
total amount should be restricted to 20–25 mL/kg/day.
Caution should be exercised in obesity, where the ideal
body weight should be considered and IV maintenance
fluid should not exceed 3 L/day. Replacement fluids
should also be governed by the composition and
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amount of fluid loss from different sources (sweat,
gastric, bile, pancreas, ileum, colon) [Figure 6b].
Recent meta‑analysis[25] suggests that prognosis with
restrictive/goal‑directed fluid therapy is better compared
with liberal fluid administration. The damage of EGL
by liberal fluid administration increased leakiness of
the endothelium. This extravasation of fluid into the
interstitium increases inflammation, wound infection
and derangement in coagulation function resulting in
increased morbidity and mortality. However, clinical
trial recommending liberal fluid over restricted in major
abdominal surgeries causing higher rate of AKI in the
restrictive fluid group is also a concern.[26] Therefore,
calculating the appropriate amount of fluid in critical
situation can be tricky and fluid responsiveness of the
patient should be assessed specially by dynamic tests
which are more sensitive. These tests are based on the
principle of inducing short‑term changes in cardiac
preload, using heart–lung interactions, by the infusion
of small volumes of fluid or by passive leg raise and
to observe the resulting effect on cardiac output. The
passive leg raise is an evidence‑based most commonly
used bedside test to detect fluid responsiveness of a
patient.
Overzealous rapid administration of IV fluids can
damage the EGL. Preloading in the presence of
normovolemia before induction of general or
neuraxial anaesthesia to combat sudden decrease in
preload is not justified. Preloading neither decreases
the incidence of vasopressor use nor hypotension but
increases the morbidity due to destruction of EGL.[27]
Rehm M et al.[2] in their study on isolated guinea pig
heart showed that unless the EGL is destroyed by
enzymes, the endothelial leakiness is not that profound
even after ischaemic insults or treatment with heparin.
The endothelium gets leaky with the extravasation of
fluid only when the protective EGL is destroyed. The
study also showed that infusion of 6% HES decreased
coronary perfusion pressure significantly, whereas
albumin and 0.9% NS had minimal effect.

EGL AND CLINICAL PATHOPHYSIOLOGY
Oedema is the accumulation of fluid in the interstitium
with an increase in interstitial compliance. Tissue
oedema occurs when the rate of transudation of fluid
in the interstitial space from the capillaries surpasses
the maximum lymphatic drainage. The mechanism of
oedema formation is different in various pathological
conditions.

Heart failure
Intact EGL has the ability to buffer an increase in
total body sodium without water retention. As a
result of heart failure, there is excessive sodium
accumulation in the body both from renal retention
and EGL degradation. The process of oedema in
acute and chronic heart failure is different. In acute
heart failure (AHF), redistribution of fluid occurs
from splanchnic and peripheral circulation due to
sympathetic activation rather than actual increase
in intravascular volume which otherwise occurs in
chronic heart failure. Hence, in accordance with
Starling forces an increase in transcapillary hydrostatic
pressure and a decrease in transcapillary oncotic
pressure gradient cause the fluid to extravasate into
the interstitium resulting in an increase in interstitial
pressure due to excessive fluid accummulation that
compromises the lymphyatic drainage. Diuretics,
ubiquitously used as a first‑line treatment of heart
failure, decreases capillary hydrostatic pressure and
thereby decreases Jv making lymphatic drainage from
the interstitium more effective and reducing oedema.
However as the protective EGL buffer is destroyed, a
large amount of sodium escapes renal clearance and
continues to contribute to oedema formation[6] and
diuretics alone are not effective. In AHF characterised
by volume redistribution, diuretics administered as
the first line of treatment can cause a decrease in left
ventricular function, an increase in ventricular filling
pressure and systemic vascular resistance by activating
renin–angiotensin–aldosterone pathway and thereby
a decrease in glomerular filtration. A combination of
vasodilators like nitrates and hydralazine, positive
pressure ventilation and ionotropes might be beneficial
in AHF to combat the sudden redistribution of fluid.
However, for chronic heart failure where there is
actual fluid retention, sodium restriction to less than
2 g/day, angiotensin‑converting enzyme inhibitors,
angiotensin receptor blockers, angiotensin receptor
neprilysin inhibitor, beta blockers and aldosterone
antagonists along with diuretics can improve oedema
and prevent cardiac remodelling.[28]
Nephrotic syndrome
The renal basement membrane has fenestrated
continuous capillaries and scanty EGL. The
fenestrations are normally around 65 nm in size which
reduces to 15 nm due to the overlaying of glycocalyx
on the fenestrations. The effective filtration pore size
at the level of podocytes is only 6 nm contributed
by the filtration slit diaphragm. Thus, with intact
basement membrane, albumin is not found in the
11
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tubular fluid and its presence depicts a breach in
capillary permeablility. In nephrotic syndrome,
oedema begins to develop before proteinuria and a
decrease in serum albumin is observed. An increase in
glycocalyx degradation product (syndecan‑1) in blood
is observed in early stages of nephrotic syndrome with
preserved renal function.
The mechanism of oedema formation in nephrotic
syndrome is complex. Decrease serum albumin,
intravascular volume status, neurohormonal factors
and an integrating mechanism of sodium retention
irrespective of intravascular volume due to activation
of epithelial sodium channels (ENaC) are thought
to be the contributing factors.[29] The mechanism
of oedema formation in nephrotic syndrome has
been described by two hypotheses, the underfill
and the overfill hypotheses. The underfill hypothesis
states that a decrease in plasma oncotic pressure
due to hypoalbuminaemia increases the Jv and
causes extravasation of fluid in the interstitial space
causing oedema. The intravascular volume loss is
sensed as hypovolemia and resultant activation
of renin–angiotensin–aldosterone system causing
secondary sodium retention. The overfill hypothesis
states it is the primary renal sodium retention that
results in oedema. Albumin can be considered as
a modality of treatment if serum albumin is below
2 g/dL, since it helps increase the plasma oncotic
pressure. Angiotensin‑converting enzyme inhibitors
and angiotensin II receptor blockers reduce the amount
of protein release in urine and help preserve plasma
oncotic pressure in nephrotic syndrome. Diuretics
increase the urine output by mobilising the fluid from
the intravascular space thereby reducing the Jv and
resulting in a decrease in Pi. The initial overburdened
lymphatics in the interstitial space because of high
Pi can now effectively drain the accumulated fluid
in the interstitium. Corticosteroids are useful, since
they help in decreasing the inflammation and prevent
disease progression.[29]
Liver cirrhosis
In cirrhosis of liver, overexpression of Aplein (APLN)
receptors activates hepatic stellate cells leading
to tissue remodelling by chronic inflammation,
neo‑angiogenesis and fibrogenesis.[30] This actively
damages the liver sinusoidal endothelial cells and
completely disrupts the architecture of the liver.
Fibrosis of the liver slows down the normal blood
flow through liver and thus increases pressure in
the portal vein. An increase in venous hydrostatic

pressure increases Jv and causes extravasation of fluid
in the interstitial space, causing oedema and ascites.
The fibrosis decreases functional hepatic units,
hampering the synthetic function of liver. This leads to
hypoalbuminaemia since synthesis of albumin is one
of the most important functions of liver. A decrease in
plasma albumin decreases plasma oncotic pressure,
thereby increasing Jv and contributing to the formation
of oedema in cirrhosis. The treatment of oedema in
cirrhosis is directed towards minimising portal venous
pressure as well as increasing the plasma oncotic
pressure. Maintaining negative sodium balance,
administering diuretics, beta blockers, paracentesis
and albumin infusion help in reducing the oedema in
such situation.[30]
Sepsis and EGL
Sepsis damages the delicate EGL by directly altering
its anionic charge and geometry and by increasing
the interendothelial gaps. Expression of endothelial
receptor adhesion molecules (ICAM 1, PECAM 1)
increases in EGL due to proinflammatory and actute
inflammatory mediators. These changes cause
leucocyte activation and promote leukocyte rolling,
adherence and migration into the interstitium by
inflicting direct damage to the vascular endothelium.
As a result, the vascular permeability increases
causing fluid and albumin to shift to the interstitial
space causing generalised oedema. The inflammatory
mediators result in loss of vascular tone, peripheral
pooling of blood and degradation of heparan
sulphate, one of the component of EGL giving rise to a
procoagulant state.
HOUR‑1 sepsis bundle recommends administration
of 30 mL/kg of crystalloids to correct hypotension and
lactate more than 4 mmol/L.[31] FEAST trial[32] comparing
40 mL/kg NS or 4% albumin volume resuscitation in
septic children had to stop midway due to increased
mortality caused by overzealous fluid resuscitation.
Buffered isotonic crystalloids are recommended, but
administration of large volumes should be avoided. IV
fluid intervention helps improve cardiac output, organ
perfusion and eventually tissue oxygenation, but the
effect is transient due to leakiness and loss of retaining
capacity of the damaged endothelium. Therefore, after
the initial fluid resuscitation, early use of vasopressors
to keep mean arterial pressure ≥65 mmHg by
increasing the stressed volume in the venous
circulation is recommended. Vasopressors augment
the mean systemic filling pressure, cardiac output and
perfusion pressure to the vital organs.
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Pulmonary vasculature and EGL
The EGL in the pulmonary vasculature is thicker than
the systemic vasculature indicating its significant role
in maintaining normal pulmonary physiology. EGL
plays a major role in mechanotrasduction and vascular
permeability. Breech in the integrity of EGL can result
in interstitial oedema and hypoxia. EGL serves as a
barrier to neutrophils, fluid and protein extravasation.
In addition it also plays a role in nitric oxide signalling
thereby modifying endothelial permeability. Acute
lung injury and acute respiratory distress syndrome
can result as a consequence of EGL disruption.
Detection of EGL degradation product in blood may
serve as an indicator of impending pulmonary damage
and its restoration by substances like clinically
therapeutic dose of heparin having anti‑inflammatory
properties can act as a promising therapeutic measure
in critically ill patients.[33]

PROTECTION OF EGL
EGL protection is gaining interest as a therapeutic
target in modern medicine. Established therapy like
blood glucose control and corticosteroids help in
protection of the EGL.[34] Some of the experimental
therapies to protect the EGL are showing promising
results. Attenuating the inflammatory damage of EGL
by inhibition of proinflammatory cytokines is one
of the suggested options. Etanercept, which treats
autoimmune diseases by inhibiting tumor necrosis
factor (TNF‑α), has been tried to preserve EGL
function.[35] ATIII has shown its efficacy in blocking
the activation of the transcription factor, nuclear
factor kB which is the regulator of innate and adaptive
immune responses, and plays an important role in
allergic airway diseases.[34] Etanercept and ATIII block
inflammatory cytokines like interleukin‑6, TNF‑α and
tissue factor genes and help protect delicate EGL.
Statins have shown to protect EGL by combating free
radical (oxidised lipoprotein) induced injury to the
endothelium and decreasing inflammatory reactants
like C‑reactive proteins.[36] However, there is lack of
evidence in favour of their use especially in patients
who are statin‑naive and have chronic kidney
disease, where studies have shown to increase the
incidence of further renal derangement.[37] Sevoflurane
protects EGL degradation by both preconditioning
and early post conditioning. Sevoflurane attenuates
liposomal cathepsin B release independent of mast
cell degranulation and looks promising in protecting
the EGL.[38] Neferine, a bisbenzylisoquinoline plant
alkaloid, probably has a promising role in protecting the

EGL by suppressing the production of mitochondrial
ROS.[39] Sulodexide is a highly purified mixture of GAGs
composed of low molecular weight heparin (80%)
and dermatan sulphate (20%) prepared from porcine
intestinal mucosa.[40] There is sufficient evidence that
sulodexide helps in regeneration of glycocalyx layer
particularly in sepsis.[40] EGL degradation markers like
syndecan‑1, heparan sulphates, heparanase, endocan,
hyaluronic acid, chondroitin and angiopoietins are
potential markers of glycocalyx damage and can be
used as a diagnostic tool for endothelial dysfunction
and sepsis severity.

SUMMARY
EGL lining nonfenestrated capillaries plays an
important role in body fluid homeostasis. The modified
Starling’s equation incorporates the importance of
EGL and subendothelial glycocalyx space in governing
transcapillary forces responsible for ultrafiltration
across the endothelial cell layer. Hence, damage to
the EGL manifests as oedema in various pathological
conditions (heart failure, liver cirrhosis, nephrotic
syndrome, sepsis and trauma), which reflects the
state of abnormal microcirculation. Therapy directed
towards preserving EGL and taking measure towards
its regeneration are currently the corner stone of
management of disease states. Fluid management in
these conditions is an ubiquitous intervention and
choosing the right amount and type of fluid is essential
to improve the quality of patient care.
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